FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...
"We are delighted to welcome these distinguished scientists and clinicians to our Scientific Advisory Board," said Dr. Neal Walker, Interim CEO and Chair of the Board of Directors of Aclaris ...